Boston Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Boston Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$3.14M	Sell	18,552 -248	-1%	-$43.9K	0.16%	166
2019 Q2	$3.45M	Sell	18,800 -8,648	-32%	-$1.51M	0.18%	150
2019 Q1	$5.05M	Sell	27,448 -8,333	-23%	-$1.54M	0.26%	109
2018 Q4	$5.93M	Sell	35,781 -1,879	-5%	-$326K	0.34%	69
2018 Q3	$7.26M	Sell	37,660 -181,726	-83%	-$32.4M	0.31%	80
2018 Q2	$37.3M	Buy	219,386 +79,212	+57%	+$12.3M	0.93%	13
2018 Q1	$22.8M	Buy	140,174 +24,054	+21%	+$3.93M	0.59%	42
2017 Q4	$17.4M	Buy	+116,120	New	+$17.2M	0.38%	74
2017 Q1	–	Sell	-183,040	Closed	-$13.5M	–	670
2016 Q4	$13.5M	Sell	183,040 -5,205	-3%	-$424K	0.32%	93
2016 Q3	$16.4M	Buy	+188,245	New	+$17.8M	0.41%	80

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Boston Advisors's VRTX Position: Q3 2019 in Review

Boston Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 1.3% in Q3 2019, selling an estimated $43.9K and leaving 18,552 shares worth $3.14M. The position accounts for 0.16% of the portfolio, ranked #166.

Boston Advisors first reported a position in VRTX in Q3 2016 and has held it in 10 quarters since. The position peaked at $37.3M in Q2 2018. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Boston Advisors held 18,552 shares of Vertex Pharmaceuticals worth $3.14M as of Q3 2019.
Boston Advisors sold 248 Vertex Pharmaceuticals shares in Q3 2019, an estimated $43.9K.
Vertex Pharmaceuticals made up 0.16% of Boston Advisors's portfolio in Q3 2019, its #166 holding.
Boston Advisors first reported a position in Vertex Pharmaceuticals in Q3 2016 and has held it in 10 quarters since.
Boston Advisors's Vertex Pharmaceuticals position peaked at $37.3M in Q2 2018.
708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.